Cory Wilhite
Nurse Practitioner · Portersville, PANPI 1316215064
Payments from drug & device makers
Across 488 payments — averaging $17.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- GSK$1K
- AbbVie$943
- Lilly USA, LLC$896
- Amgen$784
- AstraZeneca$633
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,524100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 67 | $1,160 |
| GSK | 62 | $1,094 |
| AbbVie | 70 | $943 |
| Lilly USA, LLC | 51 | $896 |
| Amgen | 43 | $784 |
| AstraZeneca | 37 | $633 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $364 |
| Johnson & Johnson | 17 | $360 |
| Pfizer | 15 | $309 |
| Biohaven Pharmaceuticals, Inc. | 15 | $250 |
| Boehringer Ingelheim | 15 | $231 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $228 |
| Novartis | 11 | $213 |
| Exact Sciences | 8 | $181 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $161 |
| Sanofi-aventis U.S. LLC | 8 | $142 |
| Axsome Therapeutics, Inc. | 4 | $87 |
| Teva Pharmaceuticals USA, Inc. | 4 | $75 |
| Esperion Therapeutics, Inc. | 4 | $68 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Daiichi Sankyo Inc. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $37 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Biogen | 2 | $32 |
| Abbott | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Medtronic | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Almatica Pharma LLC | 1 | $18 |
How this compares
$8,524 in reported general payments places this provider in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 158 | $102,298 |
| XareltoRivaroxaban | 95 | $59,814 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $47,143 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $37,248 |
| MounjaroTirzepatide | 29 | $36,705 |
| FarxigaDapagliflozin Propanediol | 50 | $35,840 |
| Repatha SureclickEvolocumab | 37 | $35,559 |
| JardianceEmpagliflozin | 39 | $33,534 |
| OzempicSemaglutide | 24 | $25,075 |
| TrulicityDulaglutide | 21 | $23,036 |
| TrintellixVortioxetine Hydrobromide | 25 | $22,846 |
| QuliptaAtogepant | 14 | $14,486 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $9,319 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,148 |
| TradjentaLinagliptin | 12 | $6,099 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $309 | $102,298158 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $1,094 | $65,61091 claims |
| Johnson & JohnsonXarelto | $360 | $59,81495 claims |
| Lilly USA, LLCMounjaro, Trulicity | $896 | $59,74150 claims |
| Boehringer IngelheimJardiance, Tradjenta | $231 | $39,63351 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $142 | $37,24847 claims |
| AstraZenecaFarxiga | $633 | $35,84050 claims |
| Novo NordiskOzempic | $1,160 | $25,07524 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $364 | $22,84625 claims |
| AbbVieQulipta | $943 | $14,48614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Portersville
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.